MA32566B1 - Anticorps neutralisant les cytomégalovirus humains et leurs utilisations - Google Patents

Anticorps neutralisant les cytomégalovirus humains et leurs utilisations

Info

Publication number
MA32566B1
MA32566B1 MA33620A MA33620A MA32566B1 MA 32566 B1 MA32566 B1 MA 32566B1 MA 33620 A MA33620 A MA 33620A MA 33620 A MA33620 A MA 33620A MA 32566 B1 MA32566 B1 MA 32566B1
Authority
MA
Morocco
Prior art keywords
antibodies
human cytomegaloviruses
neutralize human
hcmv
epitope
Prior art date
Application number
MA33620A
Other languages
Arabic (ar)
English (en)
Inventor
Antonio Lanzavecchia
Annalisa Macagno
Original Assignee
Humabs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Llc filed Critical Humabs Llc
Publication of MA32566B1 publication Critical patent/MA32566B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps neutralisants qui sont spécifiques pour les cytomégalovirus humains (hcmv); de façon spécifique les anticorps de l'invention sont spécifiques pour une combinaison des protéines de hcmv ul128, ul130 et ul131a. Les anticorps de l'invention neutralisent l'infection avec une puissance élevée. L'invention porte également sur des lymphocytes b immortalisés qui produisent de tels anticorps, sur l'épitope auquel les anticorps se lient ainsi que sur l'utilisation des anticorps et de l'épitope dans des procédés de criblage ainsi que le diagnostic et la thérapie des maladies.
MA33620A 2008-07-16 2011-02-15 Anticorps neutralisant les cytomégalovirus humains et leurs utilisations MA32566B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/002683 WO2010007463A1 (fr) 2008-07-16 2008-07-16 Anticorps neutralisant les cytomégalovirus humains et leur utilisation

Publications (1)

Publication Number Publication Date
MA32566B1 true MA32566B1 (fr) 2011-08-01

Family

ID=40430130

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33620A MA32566B1 (fr) 2008-07-16 2011-02-15 Anticorps neutralisant les cytomégalovirus humains et leurs utilisations

Country Status (17)

Country Link
EP (2) EP2303923B1 (fr)
JP (1) JP5475774B2 (fr)
KR (3) KR101407216B1 (fr)
CN (1) CN102143974B (fr)
AU (1) AU2008359583B2 (fr)
BR (1) BRPI0822989A2 (fr)
CA (1) CA2730620A1 (fr)
EA (1) EA201170204A1 (fr)
ES (1) ES2548014T3 (fr)
IL (1) IL210352A0 (fr)
MA (1) MA32566B1 (fr)
MX (1) MX2011000542A (fr)
NZ (1) NZ591055A (fr)
PT (1) PT2303923E (fr)
TN (1) TN2010000616A1 (fr)
WO (1) WO2010007463A1 (fr)
ZA (1) ZA201100489B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
PE20141432A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
WO2012006369A2 (fr) 2010-07-06 2012-01-12 Novartis Ag Immunisation de grands mammifères à l'aide de faibles doses d'arn
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
DK4066855T3 (da) 2010-08-31 2023-02-20 Glaxosmithkline Biologicals Sa Pegylerede liposomer til forsyning af RNA, der koder for immunogen
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
CN102286099B (zh) * 2011-08-05 2014-04-09 深圳市卫光生物制品股份有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
RU2660712C2 (ru) * 2012-03-27 2018-07-09 Вэриэйшн Биотекнолоджиз, Инк. Способы детекции антицитомегаловирусных нейтрализующих антител
CA2879577C (fr) * 2012-07-27 2021-08-03 City Of Hope Vaccin mva pour l'administration d'un complexe ul128 et la prevention d'une infection par cmv
WO2014099908A1 (fr) * 2012-12-17 2014-06-26 Genentech, Inc. Méthodes d'inhibition de l'infection virale chez les patient greffés
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN107325178A (zh) * 2017-06-29 2017-11-07 佛山市南海区普罗圣塔生物科技有限公司 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
MX2023009221A (es) * 2021-02-05 2023-09-11 Amgen Inc Metodos de descubrimiento de anticuerpos no terminales y ensayos unicelulares.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (fr) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Composition à action prolongée
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987003602A1 (fr) * 1985-12-06 1987-06-18 Teijin Limited Anticorps monoclonal humain contre le virus megalocytique et procede de preparation dudit anticorps
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
AU8063798A (en) 1997-06-19 1999-01-04 Regents Of The University Of California, The Secretory immunoglobulin produced by single cells and methods for making and using same
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
CN102863532A (zh) * 2004-06-21 2013-01-09 米德列斯公司 干扰素α受体1抗体及其用途
ES2546543T3 (es) * 2005-03-14 2015-09-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticuerpos monoclonales humanos contra los virus Hendra y Nipah
EP2037959B1 (fr) * 2006-06-07 2016-01-27 The Trustees Of Princeton University Complexe de protéine de surface du cytomégalovirus destiné à être utilisé dans des vaccins et en tant que cible de médicament
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof

Also Published As

Publication number Publication date
EA201170204A1 (ru) 2011-08-30
AU2008359583B2 (en) 2012-04-05
EP2303923A1 (fr) 2011-04-06
IL210352A0 (en) 2011-03-31
PT2303923E (pt) 2015-08-25
CA2730620A1 (fr) 2010-01-21
JP2011527899A (ja) 2011-11-10
ZA201100489B (en) 2013-03-27
CN102143974A (zh) 2011-08-03
ES2548014T3 (es) 2015-10-13
WO2010007463A1 (fr) 2010-01-21
NZ591055A (en) 2012-08-31
TN2010000616A1 (en) 2012-05-24
JP5475774B2 (ja) 2014-04-16
BRPI0822989A2 (pt) 2018-05-29
CN102143974B (zh) 2015-03-25
KR20150002895A (ko) 2015-01-07
EP2960250A1 (fr) 2015-12-30
KR20110055517A (ko) 2011-05-25
EP2303923B1 (fr) 2015-06-24
KR20140041951A (ko) 2014-04-04
MX2011000542A (es) 2011-08-03
AU2008359583A1 (en) 2010-01-21
KR101407216B1 (ko) 2014-06-16

Similar Documents

Publication Publication Date Title
MA32566B1 (fr) Anticorps neutralisant les cytomégalovirus humains et leurs utilisations
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
MA40497A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques du cd19
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA32577B1 (fr) Anticorps neutralisants le virus de l'influenza a et leurs utilisations
MA34524B1 (fr) Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
MA34749B1 (fr) Anticorps anti-récepteur de la barrière hémato-encéphalique à faible affinité et leurs utilisations
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MA33198B1 (fr) Anticorps anti-her di-spécifiques
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
MA33534B1 (fr) Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
MA37945A1 (fr) Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA40041A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA35928B1 (fr) Thérapie combinée d'anticorps contre le csf -1r humain et ses utilisations
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation